Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly: Why Orforglipron Matters, A Lot
04:13pm, Monday, 28'th Apr 2025
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to i
Calls of the Day: Eli Lilly
01:40pm, Monday, 28'th Apr 2025
Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
01:11pm, Monday, 28'th Apr 2025
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Eli Lilly Stock Just Got Its First Bear. Where Weight-Loss Drugs Go From Here.
12:54pm, Monday, 28'th Apr 2025
HSBC double downgraded Eli Lilly to Reduce, citing too much optimism around its new weight-loss pill, and the strength of Novo Nordisk's Ozempic brand.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
12:45pm, Monday, 28'th Apr 2025
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Eli Lilly Stock Moves Lower on Rare Double Downgrade
11:19am, Monday, 28'th Apr 2025
Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150.
BA Soars on Upgrade, LLY Double Downgrade, DPZ Earnings Slide
10:30am, Monday, 28'th Apr 2025
Domino's Pizza (DPZ) served up earnings that got cold reaction from investors. Diane King Hall talks about the company's miss and why it may need to focus more on promotions to beef up profits.
Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:20am, Monday, 28'th Apr 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
08:45am, Monday, 28'th Apr 2025
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
S&P 500 (VOO) Live: Alphabet Up, Market Down But Improving Already
07:00am, Monday, 28'th Apr 2025
Live Updates Live Coverage Has Ended All's Well That Ends Green 4:30 pm All three major market indices ended in the green Friday. The Dow Jones Industrial Average closed up a bare 0.05%, while th
How Eli Lilly and Novo Nordisk have separated themselves from their rivals
09:28pm, Friday, 25'th Apr 2025
Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the
Eli Lilly Will Be the Next $1 Trillion Stock
02:19pm, Friday, 25'th Apr 2025
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.
Trade Tracker: Bill Baruch buys Eli Lilly, McDonald's, and Palantir
01:05pm, Friday, 25'th Apr 2025
Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest portfolio moves.
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
10:19am, Friday, 25'th Apr 2025
Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds, Lilly's
Lilly requests EMA to rexamine Alzheimer's drug recommendation
10:16am, Friday, 25'th Apr 2025
Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.
